Stockpolly
Search
BFRI · NASDAQ · Medical - Pharmaceuticals

Biofrontera (BFRI)

Provides AMELUZ and RhodoLED photodynamic therapy for dermatology practices.

$1.56
Pre-market+0.05 (+2.97%)
At close$1.52(−1.30%)
Watchlist

In millions of USD, except per-share figures

In millionsQ3 FY23Sep 2023Q4 FY23Dec 2023Q1 FY24Mar 2024Q2 FY24Jun 2024Q3 FY24Sep 2024Q4 FY24Dec 2024Q1 FY25Mar 2025Q2 FY25Jun 2025Q3 FY25Sep 2025Q4 FY25Dec 2025Q1 FY26Mar 2026Q2 FY26Jun 2026
Revenue91188913997171012
Cost of revenue554455332122
Gross profit45434756516810
99999910111191310
Research & development000111111110
9998889111091110
General & administrative9900000000010
Other expenses000000000010
Operating income−5−4−5−5−5−2−5−5−67−4−1
−27−55−10000−100
Interest income000000000000
Interest expense001100000000
Other non-operating income2−84−510000110
Income before tax−64−100−6−1−4−5−76−5−1
Income tax expense000000000000
Net income from continuing operations−64−100−6−1−4−5−76−5−1
Net income−64−100−6−1−4−5−76−5−1
EPS, basic−$4.64$1.65−$2.88−$0.05−$0.98−$0.19−$0.76−$0.57−$0.62$0.48−$0.41−$0.05
EPS, diluted−$4.64$1.65−$2.88−$0.05−$0.98−$0.19−$0.76−$0.57−$0.62$0.48−$0.41−$0.05
Weighted average shares, basic1245666911121213
Weighted average shares, diluted1245666911121213
EBITDA−64−91−5−1−4−5−66−5−1
Depreciation & amortization000000000000
EBIT−64−90−6−1−4−5−76−5−1